Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7911 USD | -4.69% | +4.78% | -45.82% |
Valuation
Fiscal Period: March | 2023 |
---|---|
Capitalization 1 | 10.81 |
Enterprise Value (EV) 1 | 1.556 |
P/E ratio | -1.35 x |
Yield | - |
Capitalization / Revenue | 1,263 x |
EV / Revenue | 182 x |
EV / EBITDA | - |
EV / FCF | -573,924 x |
FCF Yield | -0% |
Price to Book | 1.18 x |
Nbr of stocks (in thousands) | 1,555 |
Reference price 2 | 6.954 |
Announcement Date | 6/14/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales 1 | 0.0999 | 0.1238 | - | 0.008561 |
EBITDA | - | - | - | - |
EBIT 1 | -0.6512 | -0.6445 | -1.734 | -5.733 |
Operating Margin | -652.05% | -520.54% | - | -66,963.68% |
Earnings before Tax (EBT) 1 | -0.7395 | -0.6729 | -1.75 | -5.458 |
Net income 1 | -0.7104 | -0.651 | -1.709 | -5.457 |
Net margin | -711.32% | -525.75% | - | -63,748.32% |
EPS 2 | -6.807 | -2.707 | -1.787 | -5.134 |
Free Cash Flow | - | -0.2291 | -0.5484 | -2.711 |
FCF margin | - | -185.06% | - | -31,666.57% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 12/27/21 | 12/27/21 | 8/12/22 | 6/14/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2023 S2 | 2024 S1 |
---|---|---|
Net sales 1 | 0.0028 | 0.0765 |
EBITDA | - | - |
EBIT | - | - |
Operating Margin | - | - |
Earnings before Tax (EBT) | - | - |
Net income | - | - |
Net margin | - | - |
EPS | - | - |
Dividend per Share | - | - |
Announcement Date | 6/14/23 | 1/12/24 |
Balance Sheet Analysis
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | 0.73 | 0.16 | - | - |
Net Cash position 1 | - | - | 0.02 | 9.26 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | -0.23 | -0.55 | -2.71 |
ROE (net income / shareholders' equity) | - | 65.7% | 173% | -142% |
ROA (Net income/ Total Assets) | - | -1,295% | -2,454% | -72.7% |
Assets 1 | - | 0.0503 | 0.0696 | 7.51 |
Book Value Per Share 2 | -10.10 | -0.7000 | -0.9800 | 5.870 |
Cash Flow per Share 2 | 0.2200 | 0.0200 | 0.0200 | 6.020 |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 12/27/21 | 12/27/21 | 8/12/22 | 6/14/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.82% | 1.96M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- VRAX Stock
- Financials Virax Biolabs Group Limited